SCHEMBL5956989

SCHEMBL5956989

Oc1ccccc1C(=S)S.S=C(S)c1cccnc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
KDM4E B2RXH2 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KMT2A Q03164 3/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 3/20 0.41
APP P05067 1/20 0.41
HCAR3 P49019 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
F7 P08709 1/20 0.40
F3 P13726 1/20 0.40
SARM1 Q6SZW1 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
SIRT6 Q8N6T7 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
SIRT3 Q9NTG7 1/20 0.40
SIRT5 Q9NXA8 1/20 0.40
SIRT4 Q9Y6E7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8694449 0.84
SCHEMBL521873 0.78 MEN1 (0.52) ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A
SCHEMBL5956988 0.77 ALDH1A1 (0.52) ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A
Hydrochloric Acid SCHEMBL27681720 0.76 MEN1 (0.50) ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A
SCHEMBL25306705 0.75 ALDH1A1 (0.49) ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A
SCHEMBL22426419 0.75 ALDH1A1 (0.56) ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A
SCHEMBL26885540 0.73 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A
Salicylic Acid SCHEMBL810750 0.72 ALDH1A1 (0.70) ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A
SCHEMBL10934521 0.71 ALDH1A1 (0.52) ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A
SCHEMBL28363683 0.70 PLOD2 (0.71) ALDH1A1KDM4ESMN1; SMN2L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651239-A1 INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID Mirus Corporation (US) 2006-05-03 EP disclosed
WO-2005004879-A1 INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID MIRUS CORPORATION (US) 2005-01-20 WO disclosed
US-20040019007-A1 Intravascular delivery of non-viral nucleic acid Arrowhead Madison Inc. 2004-01-29 US disclosed
US-20020137707-A1 Intravascular delivery of non-viral nucleic acid MONAHAN SEAN D (US) 2002-09-26 US disclosed
EP-1161547-A1 INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID Mirus Corporation (US) 2001-12-12 EP disclosed
WO-2000050617-A1 INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID MIRUS CORPORATION (US) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019007-A1 Intravascular delivery of non-viral nucleic acid HNRNPH1, HNRNPA1, HNRNPH3 ALDH1A1 4645/4885KDM4E 4775/4885SMN1; SMN2 577/4885
US-20020137707-A1 Intravascular delivery of non-viral nucleic acid NSUN2, NCL, SLC29A1 ALDH1A1 4655/4885KDM4E 4793/4885SMN1; SMN2 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.